Terry Connolly, K36 Therapeutics CEO
Atlas, F-Prime launch K36 Therapeutics to advance oncology molecule for elusive epigenetic target
After being in stealth for nearly 11 months, a new biotech has made itself known, complete with an influx of cash from some big-name investors …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
